Thrivent Financial for Lutherans Buys 299 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Thrivent Financial for Lutherans raised its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 2.3% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 13,028 shares of the specialty pharmaceutical company’s stock after acquiring an additional 299 shares during the period. Thrivent Financial for Lutherans owned approximately 0.06% of ANI Pharmaceuticals worth $777,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in ANIP. Natixis Advisors LLC grew its holdings in ANI Pharmaceuticals by 56.2% during the 3rd quarter. Natixis Advisors LLC now owns 18,184 shares of the specialty pharmaceutical company’s stock valued at $1,085,000 after purchasing an additional 6,545 shares during the last quarter. Mizuho Markets Americas LLC purchased a new position in ANI Pharmaceuticals during the 3rd quarter valued at $11,670,000. Victory Capital Management Inc. grew its position in ANI Pharmaceuticals by 153.6% in the 3rd quarter. Victory Capital Management Inc. now owns 12,919 shares of the specialty pharmaceutical company’s stock valued at $771,000 after acquiring an additional 7,825 shares during the last quarter. Summit Global Investments lifted its position in shares of ANI Pharmaceuticals by 154.2% during the third quarter. Summit Global Investments now owns 19,704 shares of the specialty pharmaceutical company’s stock worth $1,176,000 after purchasing an additional 11,952 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its position in shares of ANI Pharmaceuticals by 6.9% during the third quarter. Principal Financial Group Inc. now owns 89,961 shares of the specialty pharmaceutical company’s stock worth $5,367,000 after purchasing an additional 5,829 shares during the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CEO Nikhil Lalwani sold 33,481 shares of the stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total value of $1,941,563.19. Following the completion of the sale, the chief executive officer now directly owns 370,378 shares in the company, valued at approximately $21,478,220.22. This trade represents a 8.29 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold 33,981 shares of company stock valued at $1,970,066 in the last quarter. 12.70% of the stock is currently owned by corporate insiders.

ANI Pharmaceuticals Price Performance

ANIP opened at $56.87 on Wednesday. The firm has a market capitalization of $1.20 billion, a PE ratio of -103.40 and a beta of 0.73. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The business’s 50-day moving average is $58.14 and its two-hundred day moving average is $60.53. ANI Pharmaceuticals, Inc. has a 1 year low of $48.20 and a 1 year high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.25. The firm had revenue of $148.30 million for the quarter, compared to the consensus estimate of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The company’s quarterly revenue was up 12.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.05 EPS. Research analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.87 earnings per share for the current fiscal year.

Analyst Ratings Changes

ANIP has been the topic of several recent analyst reports. Truist Financial raised their price target on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research note on Tuesday, October 22nd. Raymond James lifted their price target on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research note on Wednesday, September 18th. Piper Sandler began coverage on ANI Pharmaceuticals in a research note on Friday, October 11th. They issued an “overweight” rating and a $68.00 price objective on the stock. StockNews.com cut ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. Finally, HC Wainwright restated a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $77.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.